骨研究ジャーナル
オープンアクセス

概要

骨転移はすべて同じではない：腎細胞癌の治療抵抗性の再考

ミカコ・スウィッツ

Renal Cell Carcinoma (RCC) is the most frequent malignancy of the kidney, accounting for 80–90% of all renal neoplasms and having a five-year overall survival rate of around 74%. Bone is the second most common location of metastasis. RCC Bone Metastases (RCCBM) treatment failure is becoming more common as patients live longer because to new RCC targeted medicines and immunotherapy. In RCC, the occurrence of bone metastases indicates a more aggressive illness with a worse prognosis. Identification of essential pathways underlying RCCBM-induced anabolic impairment could provide needed insight on how to enhance treatment results for patients with RCCBM, with the goals of limiting progression and enhancing survival.